沙库巴曲缬沙坦(LCZ696)治疗心力衰竭的研究进展

Advances in the treatment of heart failure with Sacubitril /Valsartan (LCZ696)

沙库巴曲缬沙坦(LCZ696)是近年来被批准的一种新型脑啡肽酶与血管紧张素AT1受体联合阻滞剂,用于治疗射血分数减低的心力衰竭(HFrEF)。该药是近10年来药理学进展的新突破。目前关于该药的研究主要集中在两个方面,即射血分数保留的心力衰竭(HFpEF)和急性心肌梗死后心力衰竭的应用。尤其目前正在进行的PARADISE-MI研究结果备受全球心血管病界的期待。本文就LCZ696对心力衰竭的治疗进行阐述。

LCZ696 is a new combined blocker of enkephalase and angiotensin AT1 receptor(ACE)approved in recent years for the treatment of(HFrEF)with reduced ejection fraction.The drug is a new breakthrough in pharmacology in recent 10 years.The current research focuses on the application of the drug in patients with ejection fraction reserved heart failure(HFpEF)and heart failure after acute myocardial infarction(AMI).In particular,the results of the ongoing PARADISE-MI study are expected by the global cardiovascular industry.This article describes the treatment of heart failure with LCZ696.